We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Dynamic PET acquisition-a Quantitative Technique for Grading of Malignant Tumors and Prediction of Response to Treatment

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: February 22, 2006
Last Update Posted: July 29, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Rambam Health Care Campus
To assess a quantitative kinetic model of FDG uptake measurement using PET in patients with aggressive Non-Hodgkin's lymphoma and cancer of the pancreas, malignancies with known variability in disease aggressiveness and prognosis, for optimized tailoring of the therapeutic strategy in the individual patient.

Condition Intervention Phase
Pancreatic Cancer Device: PET-CT Early Phase 1

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Dynamic FDG-PET in Aggressive Lymphoma and Pancreas Cancer

Resource links provided by NLM:

Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:
  • The impact of the imaging modality on patient management [ Time Frame: 5 years ]

Secondary Outcome Measures:
  • patient management [ Time Frame: 10 years ]

Estimated Enrollment: 70
Study Start Date: August 2006
Study Completion Date: April 2010
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with pancreatric cancer

Inclusion Criteria:

  • age>18
  • newly diagnosed untreated aggressive NHL
  • newly diagnosed untreated cancer of pancreas

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00294840

Rambam Medical Center
Haifa, Israel
Sponsors and Collaborators
Rambam Health Care Campus
Principal Investigator: Ora Israel, MD Rambam Health Care Campus
  More Information

Responsible Party: Dr. Alex Frenkel, Rambam HealthCare Campus
ClinicalTrials.gov Identifier: NCT00294840     History of Changes
Other Study ID Numbers: PETDCTIL
First Submitted: February 20, 2006
First Posted: February 22, 2006
Last Update Posted: July 29, 2010
Last Verified: May 2008

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases